Quantum Dot Imaging Agents: Haematopoietic Cell Interactions and Biocompatibility

• Published in: Cells (Basel, Switzerland) Vol. 13; no. 4; p. 354
• Main Authors: Naylor-Adamson, Leigh, Price, Thomas W, Booth, Zoe, Stasiuk, Graeme J, Calaminus, Simon D J
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-02-2024
• Subjects: Atherosclerosis; Biocompatibility; Blood; Blood vessels; Cadmium; Cadmium selenide; Cadmium telluride; Cardiovascular disease; Cardiovascular diseases; Cardiovascular system; Cell activation; Cell interactions; Cerebral infarction; Contrast agents; Diagnosis; Diagnostic imaging; Endothelium; Heart attacks; Hematopoietic stem cells; imaging; Indium; Inflammation; Ligands; Magnetic resonance imaging; Myocardial infarction; Nanoparticles; Optical properties; Physiological aspects; Polyethylene glycol; Polymers; Quantum dots; Selenium; Stroke; Technology application; Tomography; United Kingdom; quantum dots; imaging; cardiovascular diseases
• DOI: 10.3390/cells13040354
• EISSN: 2073-4409

Quantum dots (QDs) are semi-conducting nanoparticles that have been developed for a range of biological and non-biological functions. They can be tuned to multiple different emission wavelengths and can have significant benefits over other fluorescent systems. Many studies have utilised QDs with a cadmium-based core; however, these QDs have since been shown to have poor biological compatibility. Therefore, other QDs, such as indium phosphide QDs, have been developed. These QDs retain excellent fluorescent intensity and tunability but are thought to have elevated biological compatibility. Herein we discuss the applicability of a range of QDs to the cardiovascular system. Key disease states such as myocardial infarction and stroke are associated with cardiovascular disease (CVD), and there is an opportunity to improve clinical imaging to aide clinical outcomes for these disease states. QDs offer potential clinical benefits given their ability to perform multiple functions, such as carry an imaging agent, a therapy, and a targeting motif. Two key cell types associated with CVD are platelets and immune cells. Both cell types play key roles in establishing an inflammatory environment within CVD, and as such aid the formation of pathological thrombi. However, it is unclear at present how and with which cell types QDs interact, and if they potentially drive unwanted changes or activation of these cell types. Therefore, although QDs show great promise for boosting imaging capability, further work needs to be completed to fully understand their biological compatibility.